Innovative PET Radiotracer Offers Noninvasive Diagnosis for Primary Aldosteronism
New PET radiotracer provides noninvasive diagnosis for primary aldosteronism
Medical News
Image: Medical News
A new PET radiotracer, 11C-Nevanimibe, has been validated for noninvasive imaging of overactive adrenal glands, providing an alternative to invasive adrenal vein sampling for diagnosing primary aldosteronism, a condition linked to secondary hypertension.
- 01The study presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting validated the use of a PET radiotracer for diagnosing primary aldosteronism.
- 02Primary aldosteronism is a significant cause of curable secondary hypertension due to excessive aldosterone production by adrenal glands.
- 03Current diagnosis relies on adrenal vein sampling, a highly invasive procedure, which this new method aims to replace.
- 04The study involved nine participants, comparing adrenal gland uptake of the radiotracer in patients with adrenal pathology to healthy controls.
- 05The biodistribution of the radiotracer in humans aligns with previous preclinical research, indicating its potential for clinical application.
Advertisement
In-Article Ad
A recent first-in-human study has validated a novel PET radiotracer, 11C-Nevanimibe, which enables noninvasive imaging of overactive adrenal glands, offering a promising alternative to the invasive adrenal vein sampling currently used to diagnose primary aldosteronism, also known as Conn's syndrome. This condition represents a significant portion of curable secondary hypertension, where the adrenal glands produce excessive aldosterone, leading to increased blood pressure. The study, led by Benjamin Viglianti, MD PhD, at the University of Michigan, included nine participants, comprising three diagnosed with overactive adrenal glands and six healthy controls. Results indicated a higher adrenal to liver uptake ratio in patients with adrenal pathology, supporting the radiotracer's effectiveness. This advancement in molecular imaging could significantly improve diagnostic options for patients lacking noninvasive alternatives. Further clinical studies are planned to evaluate the dosimetry and efficacy of this new tracer, as highlighted by graduate student Gina Kaup.
Advertisement
In-Article Ad
This new diagnostic tool could significantly reduce the need for invasive procedures in diagnosing primary aldosteronism, leading to better patient outcomes.
Advertisement
In-Article Ad
Reader Poll
What do you think about the use of noninvasive methods for diagnosing adrenal gland conditions?
Connecting to poll...
More about University of Michigan
Read the original article
Visit the source for the complete story.